The US FDA have issued a thinly veiled rebuke to Pfizer CEO Albert Bourla, after his recent comments to Bloomberg News about Covid-19 infections rebounding after treatment with Paxlovid. Bourla … Continue reading FDA on Paxlovid rebound: “there is no evidence of benefit at this time for a longer course of treatment”